Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesOutset Medical Inc

Outset Medical Inc

Healthcare Medical Devices
PortfolioPortfolio WatchlistWatchlist
Company price
4.23 USD 0.13 ( 3.17%)
Last update at 2026-11-06T21:00:00Z
VOLUME
38598
Market Cap
59.02M

Momentum Score

…

Outset Medical, Inc., a medical technology company, engages in the development of a hemodialysis system for hemodialysis in the United States. The company provides Tablo Hemodialysis System, a compact console with integrated water purification, on-demand dialysate production, and software and connectivity capabilities; and manufactures, supports, and distributes for Tablo console, Tablo cartridge, and other consumables. It also offers Tablo Data Ecosystem, including TabloHub, a consumer-facing portal; MyTablo, a patient-facing portal; and TabloDash, an internal data analytics platform. The company was formerly known as Home Dialysis Plus, Ltd. and changed its name to Outset Medical, Inc. in January 2015. Outset Medical, Inc. was incorporated in 2003 and is headquartered in San Jose, California.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
4.04
Low
4.24
High
52 Week Price Range
3.00
Low
16.16
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Outset Medical develops commercial hemodialysis systems and single-use cartridges for in-center and home treatment, aiming to simplify therapy delivery and logistics. Long-term growth drivers include rising chronic kidney disease prevalence, policy and clinical shifts toward home-based dialysis and expansion of the installed base with associated consumable revenue that could support revenue visibility. Investors may find the integrated platform and early commercial traction appealing as adoption increases.

Major risks include strong competition from large dialysis providers and device makers, sensitivity to reimbursement and regulatory decisions, execution challenges scaling commercial and international operations, and the need to achieve consistent profitability.

Risk Score
Medium

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
4.10
Dividend Yield
-
Revenue TTM
117.80M
Revenue Per Share
6.46
Gross Profit TTM
49.20M
Debt / Equity
0.80
ROE
-59.17%
Net Debt
66.24M
ROCE
-29.41%
Diluted EPS TTM
-3.79

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -80.94M -127.48M -172.27M -162.66M -131.74M
Net income -81.65M -127.98M -172.80M -162.96M -131.94M
Selling general administrative 37.86M 43.50M 45.23M 40.52M 36.32M
Selling and marketing expenses 54.36M 70.04M 96.23M 89.48M 65.07M
Gross profit 46.75M 38.56M 29.00M 17.83M 7.61M
Reconciled depreciation 4.34M 5.73M 5.81M 5.17M 5.16M
Ebit -66.71M -107.82M -159.60M -161.02M -130.52M
Ebitda -62.37M -102.09M -153.79M -157.73M -130.02M
Depreciation and amortization 4.34M 5.73M 5.81M 3.29M 0.50M
Non operating income net other - - - 1.92M 0.50M
Operating income -66.71M -113.38M -169.77M -161.02M -130.52M
Other operating expenses 186.18M 227.06M 300.15M 276.39M 233.12M
Interest expense 13.95M 23.87M 12.68M 3.57M 1.72M
Tax provision 0.72M 0.49M 0.52M 0.29M 0.20M
Interest income 7.41M 9.76M 10.17M 3.29M 0.50M
Net interest income -6.54M -14.11M -2.50M -0.28M -1.22M
Income tax expense 0.72M 0.49M 0.52M 0.29M 0.20M
Total revenue 119.48M 113.69M 130.38M 115.38M 102.60M
Total operating expenses 113.46M 151.94M 198.77M 178.85M 138.13M
Cost of revenue 72.72M 75.12M 101.38M 97.54M 94.99M
Total other income expense net -14.22M -14.11M -2.50M -1.64M -1.22M
Net income from continuing ops -81.65M -127.98M -172.80M -162.96M -131.94M
Net income applicable to common shares - - - -162.96M -131.94M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 264.50M 275.80M 313.80M 400.12M 463.46M
Other current assets 6.00M 4.53M 5.70M 6.60M 5.53M
Total liab 137.54M 248.98M 190.91M 154.12M 89.38M
Total stockholder equity 126.95M 26.82M 122.89M 245.99M 374.08M
Other current liab 21.54M 26.96M 36.18M 41.37M 42.44M
Common stock 0.02M 0.05M 0.05M 0.05M 0.05M
Capital stock 0.02M 0.05M 0.05M 0.05M 0.05M
Retained earnings -1171.38M -1089.72M -961.75M -788.95M -625.99M
Other liab - - - 0.26M 1.03M
Other assets - - - 4.48M 33.47M
Cash 35.01M 124.01M 68.51M 73.22M 182.35M
Total current liabilities 37.63M 45.38M 55.32M 51.95M 51.70M
Current deferred revenue 13.79M 12.75M 11.73M 8.66M 6.34M
Net debt 66.24M 77.84M 67.68M 30.01M -144.54M
Short term debt 1.74M 1.80M 1.59M 1.32M 1.15M
Short long term debt total 101.25M 201.86M 136.19M 103.23M 37.81M
Other stockholder equity 1298.14M 1116.45M 1084.52M 1035.46M 1000.21M
Property plant equipment - - - 15.88M 20.20M
Total current assets 250.88M 258.22M 291.22M 373.64M 409.80M
Net tangible assets - - - 245.99M 374.08M
Short term investments 133.94M 34.67M 134.81M 214.28M 157.14M
Net receivables 28.33M 35.62M 32.98M 28.07M 25.60M
Long term debt 96.24M 197.38M 130.11M 96.34M 29.76M
Inventory 47.61M 59.39M 49.22M 51.48M 39.19M
Accounts payable 0.55M 3.86M 5.83M 0.60M 1.76M
Accumulated other comprehensive income 0.17M 0.04M 0.07M -0.56M -0.18M
Common stock total equity - - - 0.05M 0.05M
Retained earnings total equity - - - -788.95M -625.99M
Non currrent assets other 0.32M 2.17M 0.60M 4.48M 33.47M
Non current assets total 13.61M 17.57M 22.58M 26.47M 53.66M
Capital lease obligations 5.01M 4.48M 6.08M 6.89M 8.04M
Long term debt total - - - 96.34M 29.76M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments -96.89M 103.94M 7.85M -66.30M -142.51M
Change to liabilities - - - -1.46M 13.81M
Total cashflows from investing activities -97.68M 103.94M 83.03M -66.30M -142.51M
Net borrowings -106.68M 66.52M 33.23M 96.06M 64.86M
Total cash from financing activities 55.50M 67.87M 43.65M 72.90M 160.15M
Change to operating activities - - - -4.79M 15.76M
Net income -81.65M -127.98M -172.80M -162.96M -131.94M
Change in cash -88.51M 55.51M -4.70M -139.13M -112.62M
Begin period cash flow 127.34M 71.84M 76.53M 215.66M 328.28M
End period cash flow 38.84M 127.34M 71.84M 76.53M 215.66M
Total cash from operating activities -46.33M -116.30M -131.37M -145.73M -130.26M
Issuance of capital stock 161.55M 0.00M 0.00M 0.00M 149.09M
Depreciation 4.34M 5.73M 5.81M 5.17M 5.16M
Other cashflows from investing activities -97.68M 104.85M - - -142.51M
Change to inventory 11.79M -10.86M 1.65M -14.73M -22.04M
Change to account receivables 3.77M -5.01M -5.09M -2.51M -19.14M
Sale purchase of stock - - - - 149.09M
Other cashflows from financing activities 55.50M -0.94M 10.43M 104.10M 11.06M
Change to netincome - - - 31.56M 1.67M
Capital expenditures 0.80M 0.91M 3.44M 8.32M 3.11M
Change receivables - - - -2.51M -19.14M
Cash flows other operating - - - -1.26M 2.79M
Cash and cash equivalents changes - - - -139.13M -112.62M
Change in working capital 2.20M -25.69M -0.77M -21.14M -25.60M
Stock based compensation 15.62M 29.36M 38.63M 27.20M 17.45M
Other non cash items 13.17M 2.28M -2.25M 6.00M 1.59M
Free cash flow -47.12M -117.22M -134.81M -154.05M -133.37M

Peer Comparison*

Sector: Healthcare Industry: Medical Devices

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
OM
Outset Medical Inc		 0.13
3.17%		 4.23 - - 0.50 0.62 0.14 -0.24
ABT
Abbott Laboratories		 -0.03
0.03%		 109.93 25.97 17.24 3.57 3.20 3.81 16.75
MDT
Medtronic PLC		 -3.04
2.90%		 101.80 26.60 15.87 3.35 2.08 3.90 14.12
SYK
Stryker Corporation		 -9.21
2.75%		 325.87 29.23 16.86 4.18 4.51 4.63 17.16
SEMHF
Siemens Healthineers AG		 -2.15
4.12%		 49.85 39.57 21.32 3.01 3.29 2.95 16.92

Profile*

Outset Medical Inc

Outset Medical, Inc., a medical technology company, engages in the development of a hemodialysis system for hemodialysis in the United States. The company provides Tablo Hemodialysis System, a compact console with integrated water purification, on-demand dialysate production, and software and connectivity capabilities; and manufactures, supports, and distributes for Tablo console, Tablo cartridge, and other consumables. It also offers Tablo Data Ecosystem, including TabloHub, a consumer-facing portal; MyTablo, a patient-facing portal; and TabloDash, an internal data analytics platform. The company was formerly known as Home Dialysis Plus, Ltd. and changed its name to Outset Medical, Inc. in January 2015. Outset Medical, Inc. was incorporated in 2003 and is headquartered in San Jose, California.

3052 Orchard Drive, San Jose, CA, United States, 95134

669 231 8200

https://www.outsetmedical.com

310

Name Title Year Born
Ms. Leslie L. Trigg CEO & Chairman 1971
Mr. Nabeel Ahmed CFO, Principal Financial Officer & Principal Accounting Officer 1976
Mr. Martin Vazquez Chief Operating Officer 1971
Mr. Jean-Olivier Racine Chief Technology Officer 1982
Mr. John L. Brottem Gen. Counsel & Sec. 1974
Mr. James S. Mazzola Head of Investor Relations NA
Nicole Shannon Director of Marketing Communications NA
Ms. Stacey L. Porter Chief People Officer 1975
Dr. Michael Aragon M.D. Chief Medical Officer NA
Ms. Tonya Saffer Head of Gov. Affairs & Market Access NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

ITH
CAD 2.15
+27.68%
HG
CAD 4.11
+19.13%
PPTA
CAD 27.74
+17.99%
UCU
CAD 2.10
+17.32%
GAU
CAD 3.49
+16.72%
TSU
CAD 29.67
-29.71%
PXT
CAD 19.73
-16.91%
LAS-A
CAD 230.50
-9.25%
IFP
CAD 13.50
-8.35%
NFI
CAD 24.01
-7.80%

Equity Sectors*

  • Basic Materials

    +3.49%

  • Communication Services

    +0.10%

  • Consumer Cyclical

    +0.03%

  • Consumer Defensive

    +0.87%

  • Energy

    +0.64%

  • Financial Services

    +0.26%

  • Healthcare

    +2.59%

  • Industrials

    +0.89%

  • Real Estate

    +0.03%

  • Technology

    +0.88%

  • Utilities

    +0.81%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…